Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Operating Leases (2023 - 2024)

Lexicon Pharmaceuticals (LXRX) has disclosed Operating Leases for 2 consecutive years, with $5.1 million as the latest value for Q1 2024.

  • Quarterly Operating Leases changed N/A to $5.1 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Mar 2024, changed N/A year-over-year, with the annual reading at $5.3 million for FY2023, N/A changed from the prior year.
  • Operating Leases for Q1 2024 was $5.1 million at Lexicon Pharmaceuticals, down from $5.3 million in the prior quarter.
  • The five-year high for Operating Leases was $6.7 million in Q3 2023, with the low at $5.1 million in Q1 2024.